Director/PDMR Shareholding
27 oct. 2015 13h50 HE
|
AstraZeneca PLC
Transaction by Person Discharging Managerial Responsibilities
Disclosure Rule DTR 3.1.4
On 27 October 2015, Jean-Philippe Courtois, a Director of the Company notified
us that, on 6 August 2015, he...
FDA ADVISORY COMMITTEE RECOMMENDS THE APPROVAL OF LESINURAD FOR GOUT PATIENTS
26 oct. 2015 03h00 HE
|
AstraZeneca PLC
AstraZeneca has announced that the US Food and Drug Administration's
(FDA) Arthritis Advisory Committee (AAC) voted 10 to 4 to recommend the approval
of lesinurad 200mg tablets for the treatment of...
AstraZeneca Receives Complete Response Letter from US FDA for SaxaGLIPTIN / dapaGLIFLOZIN Fixed-Dose-Combination
16 oct. 2015 02h00 HE
|
AstraZeneca PLC
AstraZeneca (http://www.astrazeneca.com/) today announced that the US Food and
Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding
the New Drug Application (NDA) for the...
Holding(s) in Company - Amendment
08 oct. 2015 13h31 HE
|
AstraZeneca PLC
The 'Holding(s) in Company' announcement released on 08 October 2015 at 17.29
was released in error and should be disregarded....
ASTRAZENECA COMPLETES DIVESTMENT OF CAPRELSA
07 oct. 2015 02h00 HE
|
AstraZeneca PLC
ASTRAZENECA COMPLETES DIVESTMENT OF RARE DISEASE MEDICINE CAPRELSA
AstraZeneca has announced the global completion of the divestment of Caprelsa®
(vandetanib), a rare disease medicine, to Genzyme, a...
Director/PDMR Shareholding
01 oct. 2015 09h00 HE
|
AstraZeneca PLC
Transaction by Person Discharging Managerial Responsibilities
Disclosure Rule DTR 3.1.4
On 1 October 2015, the interest of Mr Pascal Soriot, a person discharging
managerial responsibilities, in the...
Director/PDMR Shareholding
28 sept. 2015 09h30 HE
|
AstraZeneca PLC
Transactions by Person Discharging Managerial Responsibilities
Disclosure Rule DTR 3.1.4
On 25 September 2015, Dr Sean Bohen, EVP, Global Medicines Development & Chief
Medical Officer, a person...
Director/PDMR Shareholding
28 sept. 2015 09h30 HE
|
AstraZeneca PLC
Transactions by Person Discharging Managerial Responsibilities
Disclosure Rule DTR 3.1.4
On 28 September 2015, Marc Dunoyer, Chief Financial Officer, a person
discharging managerial responsibilities,...
US FDA APPROVES EXPANDED INDICATION FOR BRILINTA TO INCLUDE LONG-TERM USE IN PATIENTS WITH A HISTORY OF HEART ATTACK
04 sept. 2015 02h00 HE
|
AstraZeneca PLC
AstraZeneca today announced that the US Food and Drug Administration (FDA) has
approved BRILINTA® (ticagrelor) tablets at a new 60mg dose to be used in
patients with a history of heart attack beyond...